93 related articles for article (PubMed ID: 23417432)
1. Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter-alpha-trypsin inhibitor and saposin B but increased expression of an inter-alpha-trypsin inhibitor heavy chain 4 fragment.
Jayapalan JJ; Ng KL; Shuib AS; Razack AH; Hashim OH
Electrophoresis; 2013 Jun; 34(11):1663-9. PubMed ID: 23417432
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.
Jayapalan JJ; Ng KL; Razack AH; Hashim OH
Electrophoresis; 2012 Jul; 33(12):1855-62. PubMed ID: 22740474
[TBL] [Abstract][Full Text] [Related]
3. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
[TBL] [Abstract][Full Text] [Related]
5. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
Alaiya AA; Al-Mohanna M; Aslam M; Shinwari Z; Al-Mansouri L; Al-Rodayan M; Al-Eid M; Ahmad I; Hanash K; Tulbah A; Bin Mahfooz A; Adra C
Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
[TBL] [Abstract][Full Text] [Related]
6. Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies.
Mohamed E; Abdul-Rahman PS; Doustjalali SR; Chen Y; Lim BK; Omar SZ; Bustam AZ; Singh VA; Mohd-Taib NA; Yip CH; Hashim OH
Electrophoresis; 2008 Jun; 29(12):2645-50. PubMed ID: 18494030
[TBL] [Abstract][Full Text] [Related]
7. High resolution two-dimensional electrophoretic analysis of urinary proteins of patients with prostatic cancer.
Grover PK; Resnick MI
Electrophoresis; 1997 May; 18(5):814-8. PubMed ID: 9194613
[TBL] [Abstract][Full Text] [Related]
8. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
9. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
10. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
[TBL] [Abstract][Full Text] [Related]
11. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.
Janković MM; Kosanović MM
Clin Biochem; 2005 Jan; 38(1):58-65. PubMed ID: 15607318
[TBL] [Abstract][Full Text] [Related]
12. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS.
Heo SH; Lee SJ; Ryoo HM; Park JY; Cho JY
Proteomics; 2007 Dec; 7(23):4292-302. PubMed ID: 17963278
[TBL] [Abstract][Full Text] [Related]
13. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer.
Sardana G; Diamandis EP
Clin Biochem; 2009 Sep; 42(13-14):1483-6. PubMed ID: 19560453
[TBL] [Abstract][Full Text] [Related]
14. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
15. Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases.
Nithipatikom K; Isbell MA; See WA; Campbell WB
Cancer Lett; 2006 Feb; 233(2):219-25. PubMed ID: 15882928
[TBL] [Abstract][Full Text] [Related]
16. Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer.
Vermassen T; Van Praet C; Lumen N; Decaestecker K; Vanderschaeghe D; Callewaert N; Villeirs G; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Prostate; 2015 Feb; 75(3):314-22. PubMed ID: 25358590
[TBL] [Abstract][Full Text] [Related]
17. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
18. [Tissue plasminogen activator in urine of patients with prostatic carcinoma and benign prostatic hyperplasia].
Zietek Z; Iwan-Zietek I; Kotschy M; Wolski Z; Kulwas A; Białkowska A
Pol Merkur Lekarski; 1997 Apr; 2(10):266-7. PubMed ID: 9377662
[TBL] [Abstract][Full Text] [Related]
19. The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients.
van den Broek I; Sparidans RW; van Winden AW; Gast MC; van Dulken EJ; Schellens JH; Beijnen JH
Proteomics Clin Appl; 2010 Dec; 4(12):931-9. PubMed ID: 21137033
[TBL] [Abstract][Full Text] [Related]
20. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
